Biden Era Ushers In New Breed of Clean-Energy Profit-Stocks
With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Here’s a brand new clean energy innovator, currently undiscovered at $2 per share, that’s deploying a world’s-first business model with 10X to 20X upside.
Get the details here...
pixel

BBIO Insider Trading (BridgeBio Pharma)

Insider Ownership Percentage: 40.32%
Insider Buying (Last 12 Months): $1,500,000.00
Insider Selling (Last 12 Months): $308,012,753.00

BridgeBio Pharma Insider Trading History Chart

BridgeBio Pharma Share Price & Price History

$54.49
▼ -3.63 (-6.25%)
As of 04/9/2021 01:00 AM ET
Days: 30 | 90 | 365
Breaking Now: Biden's Disturbing Plan to "Reset" America
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.
Go here before this message is removed.

BridgeBio Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/17/2021Brian C. StephensonInsiderBuy8,000$62.50$500,000.00  
2/17/2021Genetic Disorder L.P. KkrMajor ShareholderSell3,450,000$60.47$208,621,500.00  
2/17/2021Randal W ScottDirectorBuy16,000$62.50$1,000,000.0021,000  
12/28/2020Cameron TurtleInsiderSell19,500$69.60$1,357,200.0020,068  
12/21/2020Richard H SchellerInsiderSell60,401$65.32$3,945,393.3291,333  
12/1/2020Michael Thomas HendersonInsiderSell10,000$51.52$515,200.00284,211  
11/25/2020Cameron TurtleInsiderSell742$47.23$35,044.6616,826  
11/16/2020Michael Thomas HendersonInsiderSell10,000$45.00$450,000.00277,751  
11/5/2020Cameron TurtleInsiderSell2,500$42.05$105,125.0015,068  
11/2/2020Michael Thomas HendersonInsiderSell10,000$38.36$383,600.00277,751  
10/16/2020Charles J HomcyChairmanSell10,256$41.00$420,496.001,214,023  
9/30/2020Cameron TurtleInsiderSell14,500$37.69$546,505.0015,068  
9/29/2020Charles J. HomcyChairmanSell18,200$37.50$682,500.001,213,767  
9/25/2020Charles J. HomcyChairmanSell81,057$36.83$2,985,329.31  
9/18/2020Cameron TurtleInsiderSell2,500$42.01$105,025.0015,068  
9/15/2020Cameron TurtleInsiderSell2,500$37.06$92,650.0015,068  
8/3/2020Brian C StephensonInsiderSell4,661$27.27$127,105.47289,855  
8/3/2020Neil KumarCEOSell66,057$27.27$1,801,374.394,685,725  
7/1/2020Neil KumarCEOSell87,025$31.09$2,705,607.254,685,725  
6/30/2020Cameron TurtleInsiderSell10,000$32.66$326,600.0015,823  
6/3/2020Brian C StephensonInsiderSell1,600$30.04$48,064.00307,116  
6/3/2020Neil KumarCEOSell5,930$30.05$178,196.504,685,725  
5/28/2020Genetic Disorder L.P. KkrMajor ShareholderSell2,389,690$33.39$79,791,749.10  
5/5/2020Neil KumarCEOSell79,600$31.02$2,469,192.004,685,725  
5/4/2020Brian C StephensonInsiderSell1,494$30.00$44,820.00324,316  
5/1/2020Brian C StephensonInsiderSell7,200$29.23$210,456.00324,316  
4/27/2020Cameron TurtleInsiderSell2,000$32.01$64,020.0011,823  
4/8/2020Cameron TurtleInsiderSell8,000$27.04$216,320.0017,823  
4/7/2020Neil KumarCEOSell1,805$25.48$45,991.404,685,725  
4/3/2020Neil KumarCEOSell300$25.09$7,527.004,685,725  
4/1/2020Michael Thomas HendersonInsiderSell2,585$26.94$69,639.90170,268  
4/1/2020Neil KumarCEOSell62,117$26.26$1,631,192.424,685,725  
2/11/2020Cameron TurtleInsiderSell2,000$37.28$74,560.0011,823  
2/10/2020Charles J HomcyChairmanSell20,000$36.00$720,000.001,342,291  
2/5/2020Neil KumarCEOSell30,893$34.87$1,077,238.914,685,365  
1/14/2020Charles J. HomcyChairmanSell10,000$35.00$350,000.00  
1/8/2020Cameron TurtleInsiderSell12,807$34.37$440,176.5922,630  
1/2/2020Michael Thomas HendersonInsiderSell3,617$33.26$120,301.42  
12/30/2019Frank MccormickChairmanSell17,150$35.80$613,970.001,335,895  
12/27/2019Frank MccormickChairmanSell82,850$37.92$3,141,672.001,335,895  
7/1/2019Brian C StephensonInsiderBuy55,500$17.00$943,500.00  
7/1/2019Genetic Disorder L.P. KkrMajor ShareholderBuy2,647,100$17.00$45,000,700.00  
6/28/2019Michael Thomas HendersonInsiderBuy1,000$3.43$3,430.00
6/27/2019Global Investors Lp VikingMajor ShareholderBuy4,705,900$17.00$80,000,300.00  
See Full Table

SEC Filings (Institutional Ownership Changes) for BridgeBio Pharma (NASDAQ:BBIO)

95.53% of BridgeBio Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

BridgeBio Pharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
4/5/2021Pacer Advisors Inc.1,103$68K0.0%-48.6%0.001%
3/12/2021DekaBank Deutsche Girozentrale38,200$2.55M0.0%-4.7%0.026%
3/8/2021Dimensional Fund Advisors LP32,671$2.32M0.0%N/A0.022%
3/2/2021Norges Bank632,984$45.01M0.0%N/A0.425%
3/1/2021UBS Asset Management Americas Inc.165,402$11.76M0.0%-5.2%0.111%
2/25/2021Dimensional Fund Advisors LP32,671$2.32M0.0%N/A0.022%
2/25/2021Hsbc Holdings PLC8,757$0.62M0.0%N/A0.006%
2/24/2021Virtu Financial LLC5,622$0.40M0.0%-10.6%0.004%
2/23/2021WCM Investment Management LLC141,849$10.09M0.0%+34.1%0.095%
2/23/2021Principal Financial Group Inc.43,687$3.11M0.0%+18.7%0.029%
2/19/2021JPMorgan Chase & Co.1,354,419$96.31M0.0%+3.9%1.104%
2/18/2021US Financial Advisors LLC6,000$0.43M0.1%N/A0.005%
2/18/2021Truist Financial Corp5,694$0.41M0.0%N/A0.005%
2/17/2021Voloridge Investment Management LLC119,021$8.46M0.1%-22.7%0.097%
2/16/2021Squarepoint Ops LLC20,322$1.45M0.0%+30.3%0.017%
2/16/2021Darwin Global Management Ltd.662,958$47.14M13.2%N/A0.540%
2/16/2021Morgan Stanley74,185$5.28M0.0%+213.1%0.060%
2/16/2021Nuveen Asset Management LLC322,475$22.93M0.0%-0.1%0.263%
2/16/2021WCM Investment Management LLC141,849$10.09M0.0%+34.1%0.116%
2/16/2021Price T Rowe Associates Inc. MD30,214$2.15M0.0%+11.6%0.025%
2/16/2021Janus Henderson Group PLC1,783,535$126.83M0.1%+5.4%1.453%
2/16/2021Charles Schwab Investment Management Inc.528,443$37.58M0.0%+1.1%0.431%
2/13/2021American International Group Inc.3,342,334$237.67M0.9%-40.5%2.724%
2/12/2021Bamco Inc. NY25,876$1.84M0.0%N/A0.021%
2/12/2021Penserra Capital Management LLC2,825$0.20M0.0%+170.1%0.002%
2/12/2021Raymond James Financial Services Advisors Inc.10,940$0.78M0.0%+48.6%0.009%
2/12/2021The Manufacturers Life Insurance Company44,603$3.17M0.0%+3.2%0.036%
2/12/2021Advisory Research Inc.14,101$1M0.1%+44.4%0.011%
2/12/2021Credit Suisse AG339,060$24.11M0.0%-26.6%0.276%
2/12/2021Virtus ETF Advisers LLC4,820$0.34M0.1%-55.2%0.004%
2/12/2021M&T Bank Corp5,319$0.38M0.0%-14.9%0.004%
2/11/2021Lazard Asset Management LLC6,726$0.48M0.0%N/A0.005%
2/11/2021Northern Trust Corp832,836$59.22M0.0%-2.3%0.679%
2/11/2021Barclays PLC36,448$2.59M0.0%+9.2%0.030%
2/11/2021Citigroup Inc.540,353$38.42M0.0%-25.6%0.440%
2/11/2021Artal Group S.A.300,000$21.33M0.5%-25.0%0.244%
2/11/2021Nicholas Investment Partners LP411,771$29.28M2.3%+40.5%0.336%
2/10/2021Rhumbline Advisers91,994$6.54M0.0%+0.6%0.075%
2/10/2021Grace Capital76,900$5.47M3.5%+4.7%0.063%
2/10/2021QS Investors LLC3,142$0.22M0.0%N/A0.003%
2/10/2021Baillie Gifford & Co.118,532$8.43M0.0%+96.0%0.097%
2/9/2021Wells Fargo & Company MN72,535$5.16M0.0%+78.4%0.059%
2/9/2021Donoghue Forlines LLC24,712$1.76M0.3%N/A0.020%
2/9/2021Bank of New York Mellon Corp271,782$19.33M0.0%+9.6%0.221%
2/9/2021Illinois Municipal Retirement Fund6,657$0.47M0.0%+128.7%0.005%
2/9/2021Lord Abbett & CO. LLC1,073,966$76.37M0.2%+74.7%0.875%
2/9/2021ProShare Advisors LLC35,050$2.49M0.0%+22.4%0.029%
2/8/2021State Board of Administration of Florida Retirement System32,060$2.28M0.0%-5.6%0.026%
2/8/2021New York State Common Retirement Fund201,689$14.34M0.0%+154.5%0.164%
2/8/2021Sei Investments Co.26,766$1.90M0.0%N/A0.022%
2/8/2021Russell Investments Group Ltd.36,269$2.58M0.0%-15.6%0.030%
2/5/2021BlackRock Inc.6,517,544$463.46M0.0%+6.5%5.311%
2/5/2021Sumitomo Mitsui Trust Holdings Inc.7,628$0.54M0.0%N/A0.006%
2/5/2021SG Americas Securities LLC18,532$1.32M0.0%+22.3%0.015%
2/4/2021Los Angeles Capital Management LLC13,058$0.93M0.0%+2.6%0.009%
2/4/2021GSA Capital Partners LLP10,385$0.74M0.1%-87.0%0.008%
2/4/2021State of Wisconsin Investment Board103,900$7.39M0.0%-11.0%0.085%
2/3/2021CIBC Asset Management Inc4,338$0.31M0.0%N/A0.004%
2/2/2021California Public Employees Retirement System180,153$12.81M0.0%+9.0%0.147%
2/1/2021Victory Capital Management Inc.11,293$0.80M0.0%+7.5%0.009%
1/27/2021Chicago Partners Investment Group LLC2,883$0.20M0.0%N/A0.002%
1/27/2021Exane Derivatives495$35K0.0%N/A0.000%
1/25/2021Nisa Investment Advisors LLC5,811$0.41M0.0%+106.8%0.005%
1/25/2021Strs Ohio7,900$0.56M0.0%+49.1%0.006%
1/21/2021Cutler Group LP774$55K0.0%-22.6%0.001%
1/20/2021Pacer Advisors Inc.2,147$0.15M0.0%-41.4%0.002%
1/13/2021Sowell Financial Services LLC1,835$0.13M0.0%-33.9%0.001%
12/14/2020Strs Ohio5,300$0.20M0.0%+10.4%0.004%
12/11/2020Virtu Financial LLC6,288$0.24M0.0%N/A0.005%
11/19/2020Schonfeld Strategic Advisors LLC23,741$0.89M0.0%+77.9%0.019%
11/17/2020Paloma Partners Management Co6,437$0.24M0.0%N/A0.005%
11/17/2020Voloridge Investment Management LLC153,875$5.77M0.0%+165.6%0.126%
11/17/2020California State Teachers Retirement System110,202$4.14M0.0%+0.4%0.090%
11/17/2020Jane Street Group LLC29,983$1.13M0.0%-33.5%0.024%
11/17/2020Schonfeld Strategic Advisors LLC23,741$0.89M0.0%+77.9%0.019%
11/16/2020Cubist Systematic Strategies LLC28,801$1.08M0.0%N/A0.023%
11/16/2020AQR Capital Management LLC5,749$0.22M0.0%-87.7%0.005%
11/16/2020Squarepoint Ops LLC15,595$0.59M0.0%-10.0%0.013%
11/13/2020Morgan Stanley23,691$0.89M0.0%-60.2%0.019%
11/13/2020ProShare Advisors LLC28,646$1.08M0.0%-2.2%0.023%
11/13/2020Charles Schwab Investment Management Inc.522,543$19.61M0.0%+102.2%0.426%
11/13/2020UBS Asset Management Americas Inc.174,395$6.54M0.0%-1.4%0.142%
11/13/2020Virtus ETF Advisers LLC10,753$0.40M0.2%-11.9%0.009%
11/12/2020Advisory Research Inc.9,767$0.37M0.0%N/A0.008%
11/12/2020Grace Capital73,425$2.75M2.1%-1.3%0.060%
11/12/2020JPMorgan Chase & Co.1,303,308$48.35M0.0%+27.2%1.063%
11/12/2020Massachusetts Financial Services Co. MA415,125$15.58M0.0%-2.4%0.339%
11/12/2020Lord Abbett & CO. LLC614,724$23.06M0.1%-34.0%0.502%
11/10/2020State Street Corp2,354,508$88.34M0.0%-26.1%1.924%
11/9/2020SG Americas Securities LLC15,158$0.57M0.0%-25.0%0.012%
11/9/2020The Manufacturers Life Insurance Company43,213$1.62M0.0%-2.6%0.035%
11/9/2020Victory Capital Management Inc.10,504$0.39M0.0%-86.9%0.009%
11/9/2020State Board of Administration of Florida Retirement System33,970$1.28M0.0%+10.7%0.028%
11/6/2020BlackRock Inc.6,120,137$229.63M0.0%+10.1%5.002%
11/6/2020Trexquant Investment LP12,906$0.48M0.0%-40.6%0.011%
11/6/2020Principal Financial Group Inc.36,808$1.38M0.0%-5.0%0.030%
11/6/2020WCM Investment Management LLC105,796$3.97M0.0%+6.6%0.086%
11/6/2020GSA Capital Partners LLP79,890$3M0.5%N/A0.065%
11/5/2020California Public Employees Retirement System165,337$6.20M0.0%+2.6%0.135%
11/5/2020Wells Fargo & Company MN40,656$1.53M0.0%-14.2%0.033%
Data available starting January 2016

See Full Table
BridgeBio Pharma logo
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; and UC San Francisco. The company was founded in 2015 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $54.49
$54.02
$58.08

50 Day Range

MA: $64.61
$56.06
$71.91

52 Week Range

Now: $54.49
$25.24
$73.50

Volume

1,438,345 shs

Average Volume

1,032,015 shs

Market Capitalization

$8.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Who are the company insiders with the largest holdings of BridgeBio Pharma?

BridgeBio Pharma's top insider investors include:
  1. Neil Kumar (CEO)
  2. Charles J Homcy (Chairman)
  3. Frank Mccormick (Chairman)
  4. Charles J Homcy (Chairman)
  5. Brian C Stephenson (Insider)
  6. Michael Thomas Henderson (Insider)
  7. Richard H Scheller (Insider)
  8. Cameron Turtle (Insider)
  9. Randal W Scott (Director)
  10. Brian C Stephenson (Insider)
  11. Genetic Disorder LP Kkr (Major Shareholder)
  12. Global Investors Lp Viking (Major Shareholder)

Who are the major institutional investors of BridgeBio Pharma?

BridgeBio Pharma's top institutional investors include:
  1. Pacer Advisors Inc. — 0.00%

Which institutional investors are selling BridgeBio Pharma stock?

Within the previous quarter, BBIO stock was sold by these institutional investors:
  1. Pacer Advisors Inc.
Within the previous year, company insiders that have sold BridgeBio Pharma company stock include:
  1. Neil Kumar (CEO)
  2. Charles J Homcy (Chairman)
  3. Frank Mccormick (Chairman)
  4. Charles J Homcy (Chairman)
  5. Brian C Stephenson (Insider)
  6. Michael Thomas Henderson (Insider)
  7. Richard H Scheller (Insider)
  8. Cameron Turtle (Insider)
April 30th is approaching, are you prepared?
A new president’s policies always influence key stocks.
Here’s where top billionaires are investing.
pixel